US Patent

US12042484 — Tizanidine liquid preparation and use thereof

Method of Use · Assigned to Fidelity Biopharma Co · Expires 2042-05-07 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects a tizanidine liquid preparation and its use in treating muscle spasm.

USPTO Abstract

A tizanidine liquid preparation and use of the tizanidine liquid preparation in the preparation of a medicament for treating muscle spasm, wherein the tizanidine liquid preparation comprises an active ingredient, disodium EDTA and other pharmaceutical excipients, wherein the active ingredient is one or more of tizanidine or a pharmaceutically acceptable salt, solvate and hydrate thereof.

Drugs covered by this patent

tizanidine-hydrochloride (TIZANIDINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2779`	—	tizanidine-hydrochloride

Patent Metadata

Patent number: US12042484
Jurisdiction: US
Classification: Method of Use
Expires: 2042-05-07
Drug substance claim: No
Drug product claim: Yes
Assignee: Fidelity Biopharma Co
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.